Clinuvel Pharmaceuticals Ltd Total Liabilities
Clinuvel Pharmaceuticals Ltd total liabilities. Based on the latest financial reports, Clinuvel Pharmaceuticals Ltd (CUV) has total liabilities worth AU$20.68 Million AUD (≈ $14.63 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CUV financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Clinuvel Pharmaceuticals Ltd (2000–2025)
Total liabilities of Clinuvel Pharmaceuticals Ltd from 2000 to 2025. This chart illustrates how Clinuvel Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Clinuvel Pharmaceuticals Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Clinuvel Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Clinuvel Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tongxing Environmental Protection
SHE:003027
|
China | CN¥602.26 Million |
|
Jiangsu Huaxin New Material Co Ltd Class A
SHE:300717
|
China | CN¥282.00 Million |
|
Ratnaveer Precision Engineering Ltd
NSE:RATNAVEER
|
India | Rs5.10 Billion |
|
Beijing Piesat Information Technology Co Ltd
SHG:688066
|
China | CN¥3.81 Billion |
|
Duopharma Biotech Bhd
KLSE:7148
|
Malaysia | RM671.59 Million |
|
KPM TECH Co. Ltd
KQ:042040
|
Korea | ₩80.11 Billion |
|
Fusion Micro Finance Limited
NSE:FUSION
|
India | Rs58.39 Billion |
|
Profound Medical Corp
TO:PRN
|
Canada | CA$12.56 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Clinuvel Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Clinuvel Pharmaceuticals Ltd's balance sheet.
Liquidity & Leverage Metrics
Clinuvel Pharmaceuticals Ltd Total Liabilities Ratios Explained
Clinuvel Pharmaceuticals Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clinuvel Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clinuvel Pharmaceuticals Ltd (2000–2025)
The table below shows the annual total liabilities of Clinuvel Pharmaceuticals Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$30.94 Million ≈ $21.89 Million |
+10.06% |
| 2024-06-30 | AU$28.11 Million ≈ $19.89 Million |
-5.96% |
| 2023-06-30 | AU$29.89 Million ≈ $21.15 Million |
+55.25% |
| 2022-06-30 | AU$19.25 Million ≈ $13.62 Million |
+95.88% |
| 2021-06-30 | AU$9.83 Million ≈ $6.96 Million |
+3.75% |
| 2020-06-30 | AU$9.48 Million ≈ $6.70 Million |
+83.43% |
| 2019-06-30 | AU$5.17 Million ≈ $3.65 Million |
+48.07% |
| 2018-06-30 | AU$3.49 Million ≈ $2.47 Million |
+10.30% |
| 2017-06-30 | AU$3.16 Million ≈ $2.24 Million |
+37.30% |
| 2016-06-30 | AU$2.30 Million ≈ $1.63 Million |
-5.53% |
| 2015-06-30 | AU$2.44 Million ≈ $1.73 Million |
+41.30% |
| 2014-06-30 | AU$1.73 Million ≈ $1.22 Million |
-12.64% |
| 2013-06-30 | AU$1.98 Million ≈ $1.40 Million |
-16.22% |
| 2012-06-30 | AU$2.36 Million ≈ $1.67 Million |
-37.24% |
| 2011-06-30 | AU$3.76 Million ≈ $2.66 Million |
+21.97% |
| 2010-06-30 | AU$3.08 Million ≈ $2.18 Million |
-32.48% |
| 2009-06-30 | AU$4.56 Million ≈ $3.23 Million |
+44.56% |
| 2008-06-30 | AU$3.16 Million ≈ $2.23 Million |
+29.73% |
| 2007-06-30 | AU$2.43 Million ≈ $1.72 Million |
-21.06% |
| 2006-06-30 | AU$3.08 Million ≈ $2.18 Million |
+18.48% |
| 2005-06-30 | AU$2.60 Million ≈ $1.84 Million |
+86.82% |
| 2004-06-30 | AU$1.39 Million ≈ $985.24K |
+160.05% |
| 2003-06-30 | AU$535.45K ≈ $378.87K |
+153.98% |
| 2002-06-30 | AU$210.83K ≈ $149.17K |
-33.76% |
| 2001-06-30 | AU$318.26K ≈ $225.19K |
+157.62% |
| 2000-06-30 | AU$123.54K ≈ $87.41K |
-- |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more